Healthcare solutions provider Solventum (NYSE: SOLV) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was 33.8% above analysts’ consensus estimates.
Is now the time to buy Solventum? Find out by accessing our full research report, it’s free.
Solventum (SOLV) Q2 CY2026 Highlights:
- Revenue: $2.21 billion vs analyst estimates of $2.15 billion (2.2% year-on-year growth, 2.5% beat)
- Adjusted EPS: $2.55 vs analyst estimates of $1.91 (33.8% beat)
- Management raised its full-year Adjusted EPS guidance to $7.15 at the midpoint, a 10% increase
- Operating Margin: 8.2%, down from 9.9% in the same quarter last year
- Free Cash Flow Margin: 6.5%, up from 2.7% in the same quarter last year
- Organic Revenue rose 9.5% year on year (beat)
- Market Capitalization: $15.23 billion
"The Solventum team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformation," said Bryan Hanson, chief executive officer of Solventum.
Company Overview
Founded in 1985, Solventum (NYSE: SOLV) develops, manufactures, and commercializes a portfolio of healthcare products and services addressing critical customer and therapeutic patient needs.
Revenue Growth
A company’s long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Unfortunately, Solventum struggled to consistently increase demand as its $8.31 billion of sales for the trailing 12 months was close to its revenue four years ago. This was below our standards and is a sign of poor business quality.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a stretched historical view may miss recent innovations or disruptive industry trends. Just like its four-year trend, Solventum’s revenue over the last two years was flat, suggesting it is in a slump. 
We can better understand the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Solventum’s organic revenue averaged 3.4% year-on-year growth. Because this number is better than its two-year revenue growth, we can see that some mixture of divestitures and foreign exchange rates dampened its headline results. 
This quarter, Solventum reported modest year-on-year revenue growth of 2.2% but beat Wall Street’s estimates by 2.5%.
Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months. This projection doesn’t excite us and suggests its newer products and services will not accelerate its top-line performance yet.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Cash Is King
If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.
Solventum has shown impressive cash profitability, giving it the option to reinvest or return capital to investors. The company’s free cash flow margin averaged 12% over the last five years, better than the broader healthcare sector.
Taking a step back, we can see that Solventum’s margin dropped by 18.2 percentage points during that time. If its declines continue, it could signal increasing investment needs and capital intensity.
Solventum’s free cash flow clocked in at $144 million in Q2, equivalent to a 6.5% margin. This result was good as its margin was 3.8 percentage points higher than in the same quarter last year, but we wouldn’t read too much into the short term because investment needs can be seasonal, causing temporary swings. Long-term trends carry greater meaning.
Key Takeaways from Solventum’s Q2 Results
We were impressed by how significantly Solventum blew past analysts’ organic revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a solid print. The stock traded up 3.7% to $90.75 immediately following the results.
Sure, Solventum had a solid quarter, but if we look at the bigger picture, is this stock a buy? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
